Banned Devices; Proposal To Ban Electrical Stimulation Devices Used To Treat Self-Injurious or Aggressive Behavior; Extension of Comment Period, 32258-32259 [2016-12026]
Download as PDF
32258
Federal Register / Vol. 81, No. 99 / Monday, May 23, 2016 / Proposed Rules
(a) Comments Due Date
We must receive comments by July 7, 2016.
(b) Affected ADs
None.
(c) Applicability
This AD applies to Airbus Model A300B4–
203 and A300B4–2C airplanes, certificated in
any category, manufacturer serial numbers
210, 212, 218, 220, 227, 234, 235, 236, 239,
247, 255, 256, 259, 261, 274, 277, 292, 299,
and 302.
(d) Subject
Air Transport Association (ATA) of
America Code 54, Nacelles/Pylons.
(e) Reason
This AD was prompted by cracks found on
pylon side panels (upper section) at rib 8. We
are proposing this AD to detect and correct
cracking of the pylon side panels. Such
cracking could result in pylon structural
failure and in-flight loss of an engine.
(f) Compliance
Comply with this AD within the
compliance times specified, unless already
done.
(g) Detailed Inspection of Pylons and
Corrections
At the applicable time specified in Airbus
Service Bulletin A300–54–0075, Revision 04,
dated May 26, 2015: Do a detailed inspection
for crack indications of the pylons 1 and 2
side panels (upper section) at rib 8, in
accordance with the Accomplishment
Instructions of Airbus Service Bulletin A300–
54–0075, Revision 04, dated May 26, 2015.
sradovich on DSK3TPTVN1PROD with PROPOSALS
(h) Crack Confirmation
If any crack indication is found during the
inspection required by paragraph (g) of this
AD: Before further flight, do a high frequency
eddy current (HFEC) inspection to confirm
the crack, in accordance with the
Accomplishment Instructions of Airbus
Service Bulletin A300–54–0075, Revision 04,
dated May 26, 2015.
(i) Follow-On Actions for No Crack/
Indication
If the inspection required by paragraph (g)
of this AD reveals no crack indication, or if
the HFEC inspection specified by paragraph
(h) of this AD confirms no crack: Do the
actions specified in either paragraph (i)(1) or
(i)(2) of this AD.
(1) Repeat the inspection required by
paragraph (g) of this AD at the applicable
time specified in Airbus Service Bulletin
A300–54–0075, Revision 04, dated May 26,
2015.
(2) At the applicable time specified in
Airbus Service Bulletin A300–54–0081,
dated August 11, 1993: Modify the pylons, in
accordance with Airbus Service Bulletin
300–54–0081, dated August 11, 1993.
Thereafter, repeat the HFEC inspection
specified in paragraph (h) of this AD at the
applicable interval specified in Airbus
Service Bulletin A300–54–0075, Revision 04,
dated May 26, 2015, and repair any crack
before further flight using a method approved
by the Manager, International Branch, ANM–
VerDate Sep<11>2014
16:06 May 20, 2016
Jkt 238001
116, Transport Airplane Directorate, FAA; or
the European Aviation Safety Agency
(EASA); or Airbus’s EASA Design
Organization Approval (DOA).
(j) Follow-On Actions for Crack Findings
If any crack is confirmed during the
inspection required by paragraph (h) of this
AD, repair before further flight using a
method approved by the Manager,
International Branch, ANM–116, Transport
Airplane Directorate, FAA; or EASA; or
Airbus’s EASA DOA.
(k) Credit for Previous Actions
This paragraph provides credit for actions
required by paragraphs (g), (h), (i), and (j) of
this AD, if those actions were performed
before the effective date of this AD using the
service information specified in paragraphs
(k)(1) through (k)(4) of this AD.
(1) Airbus Service Bulletin A300–54–0075,
dated August 11, 1993, which was
incorporated by referenced in AD 2010–06–
04, Amendment 39–16228 (75 FR 11428,
March 11, 2010); corrected May 4, 2010 (75
FR 23572).
(2) Airbus Service Bulletin A300–54–0075,
Revision 01, dated November 9, 2007, which
is not incorporated by reference in this AD.
(3) Airbus Service Bulletin A300–54–0075,
Revision 02, dated June 26, 2008, which is
not incorporated by reference in this AD.
(4) Airbus Service Bulletin A300–54–0075,
Revision 03, dated March 27, 2013, which is
not incorporated by reference in this AD.
(l) Other FAA AD Provisions
The following provisions also apply to this
AD:
(1) Alternative Methods of Compliance
(AMOCs): The Manager, International
Branch, ANM–116, FAA, has the authority to
approve AMOCs for this AD, if requested
using the procedures found in 14 CFR 39.19.
In accordance with 14 CFR 39.19, send your
request to your principal inspector or local
Flight Standards District Office, as
appropriate. If sending information directly
to the International Branch, send it to ATTN:
Dan Rodina, Aerospace Engineer,
International Branch, ANM–116, Transport
Airplane Directorate, FAA, 1601 Lind
Avenue SW., Renton, WA 98057–3356;
telephone 425–227–2125; fax 425–227–1149.
Information may be emailed to: 9-ANM-116AMOC-REQUESTS@faa.gov. Before using
any approved AMOC, notify your appropriate
principal inspector, or lacking a principal
inspector, the manager of the local flight
standards district office/certificate holding
district office. The AMOC approval letter
must specifically reference this AD.
(2) Contacting the Manufacturer: For any
requirement in this AD to obtain corrective
actions from a manufacturer, the action must
be accomplished using a method approved
by the Manager, International Branch, ANM–
116, Transport Airplane Directorate, FAA; or
the EASA; or Airbus’s EASA DOA. If
approved by the DOA, the approval must
include the DOA-authorized signature.
(m) Related Information
(1) Refer to Mandatory Continuing
Airworthiness Information (MCAI) EASA
Airworthiness Directive 2015–0201, dated
PO 00000
Frm 00003
Fmt 4702
Sfmt 4702
October 7, 2015, for related information. This
MCAI may be found in the AD docket on the
Internet at https://www.regulations.gov by
searching for and locating Docket No. FAA–
2016–6671.
(2) For service information identified in
this AD, contact Airbus SAS, Airworthiness
Office—EAW, 1 Rond Point Maurice
Bellonte, 31707 Blagnac Cedex, France;
telephone +33 5 61 93 36 96; fax +33 5 61
93 44 51; email account.airworth-eas@
airbus.com; Internet https://www.airbus.com.
You may view this service information at the
FAA, Transport Airplane Directorate, 1601
Lind Avenue SW., Renton, WA. For
information on the availability of this
material at the FAA, call 425–227–1221.
Issued in Renton, Washington, on May 11,
2016.
Suzanne Masterson,
Acting Manager, Transport Airplane
Directorate, Aircraft Certification Service.
[FR Doc. 2016–11681 Filed 5–20–16; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 882 and 895
[Docket No. FDA–2016–N–1111]
Banned Devices; Proposal To Ban
Electrical Stimulation Devices Used To
Treat Self-Injurious or Aggressive
Behavior; Extension of Comment
Period
AGENCY:
Food and Drug Administration,
HHS.
Proposed rule; extension of
comment period.
ACTION:
The Food and Drug
Administration (FDA) is extending the
comment period for the proposed rule
that appeared in the Federal Register of
April 25, 2016. In the proposed rule,
FDA requested comments for a ban on
electrical stimulation devices (ESDs)
used for self-injurious or aggressive
behavior (SIB or AB). The Agency is
taking this action in response to
requests for an extension to allow
interested persons additional time to
submit comments.
DATES: FDA is extending the comment
period on the proposed rule published
April 25, 2016 (81 FR 24386). Submit
either electronic or written comments
by July 25, 2016.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
E:\FR\FM\23MYP1.SGM
23MYP1
Federal Register / Vol. 81, No. 99 / Monday, May 23, 2016 / Proposed Rules
sradovich on DSK3TPTVN1PROD with PROPOSALS
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–1111 for ‘‘Proposal to Ban
Electrical Stimulation Devices Used to
Treat Self-Injurious or Aggressive
Behavior.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
VerDate Sep<11>2014
16:06 May 20, 2016
Jkt 238001
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Rebecca Nipper, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1540, Silver Spring,
MD 20993–0002, 301–796–6527.
In the
Federal Register of April 25, 2016, FDA
published a proposed rule with a 30-day
comment period to request comments
on a proposal to ban ESDs used for SIB
or AB. Comments on the proposed ban
will inform FDA’s rulemaking.
The Agency has received requests for
a 60-day extension of the comment
period for the proposed rule. Each
request conveyed concern that the
current 30-day comment period does
not allow sufficient time to develop a
meaningful or thoughtful response to
the proposed rule.
FDA has considered the requests and
is extending the comment period for the
proposed rule for 60 days, until July 25,
2016. The Agency believes that a 60-day
extension allows adequate time for
interested persons to submit comments
without significantly delaying
rulemaking on this important issue.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00004
Fmt 4702
Sfmt 4702
32259
Dated: May 17, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–12026 Filed 5–20–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF THE INTERIOR
Bureau of Ocean Energy Management
30 CFR Part 550
[Docket ID: BOEM–2013–0081]
RIN 1010–AD82
Air Quality Control, Reporting, and
Compliance
Bureau of Ocean Energy
Management (BOEM), Interior.
ACTION: Proposed rule; notice of
extension of public comment period.
AGENCY:
BOEM is extending the public
comment period to submit comments on
the proposed rule entitled ‘‘Air Quality
Control, Reporting, and Compliance,’’
which was published in the Federal
Register on April 5, 2016. The original
public comment period to submit
comments on this rulemaking would
have ended on June 6, 2016. However,
BOEM has received public comments
requesting an extension of the comment
period. BOEM has reviewed the
extension requests and has determined
that a 14-day comment period extension
to June 20, 2016, is appropriate. The
proposed rule specified a separate,
shorter period to submit comments to
the Office of Management and Budget
on the information collection (IC)
burden in this rulemaking. That
comment period ended on May 5, 2016,
and will not be extended.
DATES: The comment period for
comments on the substance of the
proposed rule published on April 5,
2016 (81 FR 19717), has been extended.
Written comments must be received by
the extended due date of June 20, 2016.
BOEM may not fully consider comments
received after this date.
ADDRESSES: You may submit comments
identified by the number 1010–AD82,
by any of the following methods:
• Federal rulemaking portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Department of the Interior,
Bureau of Ocean Energy Management,
Office of Policy, Regulation and
Analysis, Attention: Peter Meffert,
45600 Woodland Road, Sterling,
Virginia 20166.
• Hand delivery: Front Desk,
Department of the Interior, Bureau of
SUMMARY:
E:\FR\FM\23MYP1.SGM
23MYP1
Agencies
[Federal Register Volume 81, Number 99 (Monday, May 23, 2016)]
[Proposed Rules]
[Pages 32258-32259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12026]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 882 and 895
[Docket No. FDA-2016-N-1111]
Banned Devices; Proposal To Ban Electrical Stimulation Devices
Used To Treat Self-Injurious or Aggressive Behavior; Extension of
Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is extending the
comment period for the proposed rule that appeared in the Federal
Register of April 25, 2016. In the proposed rule, FDA requested
comments for a ban on electrical stimulation devices (ESDs) used for
self-injurious or aggressive behavior (SIB or AB). The Agency is taking
this action in response to requests for an extension to allow
interested persons additional time to submit comments.
DATES: FDA is extending the comment period on the proposed rule
published April 25, 2016 (81 FR 24386). Submit either electronic or
written comments by July 25, 2016.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
[[Page 32259]]
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-1111 for ``Proposal to Ban Electrical Stimulation Devices
Used to Treat Self-Injurious or Aggressive Behavior.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Rebecca Nipper, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1540, Silver Spring, MD 20993-0002, 301-796-6527.
SUPPLEMENTARY INFORMATION: In the Federal Register of April 25, 2016,
FDA published a proposed rule with a 30-day comment period to request
comments on a proposal to ban ESDs used for SIB or AB. Comments on the
proposed ban will inform FDA's rulemaking.
The Agency has received requests for a 60-day extension of the
comment period for the proposed rule. Each request conveyed concern
that the current 30-day comment period does not allow sufficient time
to develop a meaningful or thoughtful response to the proposed rule.
FDA has considered the requests and is extending the comment period
for the proposed rule for 60 days, until July 25, 2016. The Agency
believes that a 60-day extension allows adequate time for interested
persons to submit comments without significantly delaying rulemaking on
this important issue.
Dated: May 17, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-12026 Filed 5-20-16; 8:45 am]
BILLING CODE 4164-01-P